Drug delivery devices: nasal, pulmonary, injectable. US-listed access to the delivery-device node. Less pure than WST/STVN but diversified across delivery modalities.
Conviction●○○○○1 of 5
Research target—Snapshot target
Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap$8.10BSnapshot value
Biologics self-administration shift driving device demand; GLP-1 device attach rate; nasal/pulmonary drug delivery growth; connected device adoption.
Segment dilution (broader dispensing/closure businesses); less direct GLP-1 exposure than WST/STVN; competitive pressure in delivery devices.
needs X/Reddit sentiment sweep
Snapshot · Not reviewed🟢 Lean-Bull · ins-$1.6M · 13F 16+/8- · short↓0.29
Snapshot · Not reviewed